Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Floquet

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
The Oncologist|August 22, 2012
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)Patricia Pautier, Anne Floquet, Nicolas Penel, et al.
Bulletin Du Cancer|March 2, 2023
[Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups]Bérénice Collineau, Catherine Genestie, Sabrina Croce, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 20, 2022
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancerSarah Betrian, Martina Aida Angeles, Antonio Gil Moreno, et al.
Cancers|January 13, 2021
Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)Khalil Hodroj, Aleksandra Stevovic, Valery Attignon, et al.
Cancers|May 14, 2022
Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques NetworkHélène Bonsang-Kitzis, Nabilah Panchbhaya, Anne-Sophie Bats, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Predictors of early death risk in older patients treated with first-line chemotherapy for cancerPierre Soubeyran, Marianne Fonck, Christèle Blanc-Bisson, et al.
International Journal of Environmental Research and Public Health|June 10, 2023
One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV StudyBrice Richez, Coralie Cantarel, Françoise Durrieu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 17, 2019
Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasmsSabrina Croce, Isabelle Hostein, Teri A Longacre, et al.
Bulletin Du Cancer|December 29, 2006
[SOR SAVOIR PATIENT Cancer and fatigue. Information dedicated to cancer patients and relatives]Pascale Dielenseger, Jean-Marie Dilhuydy, Sylvie Brusco, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 18, 2020
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)Isabelle Ray-Coquard, Helen Hatcher, Emmanuelle Bompas, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
The Oncologist|August 22, 2012
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)Patricia Pautier, Anne Floquet, Nicolas Penel, et al.
Bulletin Du Cancer|March 2, 2023
[Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups]Bérénice Collineau, Catherine Genestie, Sabrina Croce, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 20, 2022
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancerSarah Betrian, Martina Aida Angeles, Antonio Gil Moreno, et al.
Cancers|January 13, 2021
Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)Khalil Hodroj, Aleksandra Stevovic, Valery Attignon, et al.
Cancers|May 14, 2022
Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques NetworkHélène Bonsang-Kitzis, Nabilah Panchbhaya, Anne-Sophie Bats, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Predictors of early death risk in older patients treated with first-line chemotherapy for cancerPierre Soubeyran, Marianne Fonck, Christèle Blanc-Bisson, et al.
International Journal of Environmental Research and Public Health|June 10, 2023
One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV StudyBrice Richez, Coralie Cantarel, Françoise Durrieu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 17, 2019
Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasmsSabrina Croce, Isabelle Hostein, Teri A Longacre, et al.
Bulletin Du Cancer|December 29, 2006
[SOR SAVOIR PATIENT Cancer and fatigue. Information dedicated to cancer patients and relatives]Pascale Dielenseger, Jean-Marie Dilhuydy, Sylvie Brusco, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 18, 2020
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)Isabelle Ray-Coquard, Helen Hatcher, Emmanuelle Bompas, et al.
Pageof 10